![]() |
|
![]() |
||||||||||||||||||||
![]() |
||||||||||||||||||||||
INTRODUCTION About the Menopause
Menopause is defined as the cessation of menstruation as a result of the
decline in ovarian function. Technically, you enter menopause following
12 consecutive months without a period.
“Menopause signals the end of fertility
and the beginning of a new and potentially rewarding time in a woman's
life.”
The menopause occurs in all women at some
stage. Natural menopause occurs when the ovaries fail to produce the female
sexual hormone estrogen and progesterone. Hormone production fails when
the ovaries have few remaining egg cells.
Periods stop or become infrequent because
the reduced levels of estrogen and progesterone do not stimulate the endometrium
as they usually would in a normal cycle. Hormone levels can fluctuate
for many years, before finally reaching a low, at which the endometrium
remains thin and no longer bleeds.
The average age of the natural menopause
is 51 years, but this can vary quite significantly. In rare cases, menopause
can occur as early as the 30's or as late as the 60's. Menopause is classed
as premature if it occurs before a woman reaches the age of 40. Radiation
exposure, chemotherapeutic drugs and surgery can create what is known
as an artificial menopause.
Several factors may contribute to the
early onset of menopause, for example a history of smoking, poor nutrition
or a co-existing medical condition.
Menopausal symptoms include a range of
physical, psychological and sexual problems. Most common are hot flushes,night sweats,insomnia,irritability,mood swings,depression
and dryness of the
vagina. There are, of course, many more reported symptoms.
These complaints are due to an increasing
deficiency in the body’s natural hormones (especially estrogen). A lack
of estrogen also contributes to the increased risk of osteoporosis.
Hormonal information
The first two weeks of the menstrual cycle are dominated by estrogen.
It is their role to build the lining of the uterus (this is done in preparation
for a potential pregnancy). It is on approximately day 14 of the cycle
that an egg is released from the ovaries. This process is called ovulation.
After ovulation has taken place the ovary
begins to produce progesterone. It is during the second half of the cycle
that progesterone is dominant. The role of progesterone is to change the
character of the uterine lining, (again in preparation for pregnancy)
and stop any further buildup of the lining by estrogen. If, at the end
of the cycle, the egg has not been fertilised, both estrogen and progesterone
levels drop. This drop in hormone levels causes the uterine lining to
be sloughed off (a menstrual bleeding occurs). The female body goes through
this cycle monthly in preparation for a potential pregnancy.
At birth, a female has almost a million
eggs, but by puberty they have only 300,000. During the 10 to 15 years
before the menopause, the rate at which these eggs are lost accelerates.
Perimenopause is the term used to describe
the transitional period between a woman's reproductive years and the time
when menstruation ceases completely.
Generally perimenopause occurs between
the ages of 40 and 51. Its duration can vary hugely; between six months
and ten years. Hormone levels naturally fluctuate and decline, but the
process is not necessarily a smooth and well-ordered one.
Changes in hormone levels are a major
contributing factor in the occurrence of the physical, mental, and emotional
imbalances that are common in many women’s menopausal experiences.
Eventually estrogens reach a level
at which the lining of the uterus discontinues to builds up and menstruation
finally stops. This point is the menopause.
“Although there are similarities
in what happens hormonally, each woman's experience can be very different.
Genetics may play a role in the timing, but lifestyle can certainly influence
a woman's experience of menopause.”
Symptoms and complaints
Menopause symptoms affect around
70% women.
Symptoms such as hot flushes, night sweats, palpitations,dizziness, insomnia and headaches/joint aches are particularly
common in the early stages of menopause.
In the later stages of the menopause,
changes in the bladder and vagina occur due to the lack of estrogen. For
example, increased urinary frequency/incontinence/discomfort, urine infection,
vaginal dryness/discomfort/discharge and burning or itching.
Vaginal dryness can make sexual intercourse
painful or uncomfortable. Women may also find their interest in sex decreases,
and orgasms become less intense. This is again due to decreased levels
of estrogens.
Such complaints can be very distressing
and embarrassing.
Vaginal and bladder symptoms are very
common and can cause significant distress yet are often under-reported
and under-treated. Women are frequently too embarrassed to discuss these
problems. Very effective treatments are available and should be discussed.
Other later menopausal symptoms stem from
the decrease in collagen production. Collagen production is reduced by
the falling levels of estrogen, which in turn, causes skin to lose its
elasticity and become dry and thinner. It becomes more prone to bruising,
and the development of wrinkles may be accelerated. Estrogen deficiency
is also believed to be a contributing factor in hair dryness and thinning/loss.
Osteoporosis
Women show a particularly marked rise
in osteoporosis risk after their estrogen production falls at menopause.
Aging and falling estrogen levels increase loss of bone mineral density,
which ultimately leads to bone thinning and fragility (osteoporosis).
Bone loss affects both sexes as they age however; the rate of bone loss
is significantly greater in women. In the first five years after menopause,
some women may lose as much as 15% of their bone mass. Hence, osteoporosis
is far more common in women than men.
Osteoporosis is defined as a systemic
skeletal disease characterised by low bone mass and microarchitectural
deterioration of bone tissue, with a consequent increase in bone fragility
and susceptibility to fracture.
Worldwide, the lifetime risk for osteoporotic
fractures in women may be as high as 40%; in men it is 13%. It is estimated
that osteoporosis affects one in three post-menopausal women.
Bone loss alone does not cause any symptoms,
(but can cause the sufferer severe pain) however the increase fragility
means a simple fall could end in fracture. Fractures commonly occur in
the wrist, spine and hip. Such fractures can significantly alter quality
of life.
The major osteoporotic complications are
fractures of the hip and of the spine. The mortality rate for those suffering
hip fractures varies from 15% to 30% owing to secondary complications
such as pneumonia. Hip fractures are associated with considerable morbidity,
lengthy hospital admissions and a correspondingly large economic burden.
Worldwide, the number of hip fractures
could rise from 1.7 million in 1990 to 6.3 million by 2050, with the most
dramatic rise expected to be in Asia over the next few decades as the
population there both grows and ages.
(Bulletin of the World Health Organisation 1999)
Hormone Replacement Therapy
(HRT)
HRT is prescribed as a first line treatment for the relief of menopausal
symptoms. It eliminates or relieves symptoms such as hot flushes, night
sweats, insomnia, mood swings, migraine and a number of vaginal problems.
HRT is also licensed as secondary treatment
of the potentially life threatening disease osteoporosis.
HRT is a well established and well researched
form of medication. It has been available for over 50 years. It’s effectiveness
in the treatment of menopausal symptoms as well as its bone protecting
properties have been proven in numerous studies.
The vast majority of women taking HRT
are very satisfied with the results. HRT can completely alter a woman’s
life.
Hormone Replacement Therapy works by restoring
the body’s premenopausal level of estrogens. This results in menopausal
symptoms being relieved.
Most common of the HRT types currently
available is what is known as “sequential combined” HRT. This means a
progestogen is added during the second half of a 28 day treatment.
Women who still have an intact uterus
are advised to take HRT with an added progestogen. Also popular is “continuous
combined” HRT, as the name suggests the progestogen is taken continuously
throughout the 28 day treatment.
Unopposed estrogen (with no added progestogen)
stimulates the thickening of the uterine lining, which is at risk of becoming
cancerous. The progestogen protects the uterus from such unwanted effects.
Some progestogens have even been found to enhance estrogen’s beneficial
effects on symptomatic relief and bone mineral density.
For those women without an intact uterus,
“mono-therapy” is suitable (unopposed estrogen).
There are several different forms (e.g.
tablet, cream, patch) of hormone replacement therapy available today.
Oral (tablet) HRT is, by far, the most commonly prescribed of these. It
is also best tolerated among patients.
There are two forms of estrogens used in preparations today; conjugated
equine estrogens and those estrogens derived from plants.
Conjugated equine estrogens are obtained
from the urine of pregnant mares. This type does not conform to the natural
estrogens produced by the body but do have an estrogen-like effect.
17-beta estradiol is synthetically manufactured
using natural plant sources such as yam and soy. It is identical to the
estrogen produced in the human female body.
This type of estrogen is widely preferred
due to its natural properties. A recent survey of physicians found over
75% favoured 17-beta estradiol over other types of estrogens. (HRT marketing
understanding 2002) .
Resource Medical UK Ltd offers
BEDOL.
All progestogens used are synthetically manufactured. They are different
to the progestogen produced in the human body but this is not a bad thing.
They can be tailored to promote additional positive effects. Most progestogens
are made from plant sources.
Progestogens are either progesterone (e.g.
medroxyprogesterone acetate) or testosterone derivatives (e.g. norethisterone).
Progesterone derivatives more closely resemble natural hormones.
The key role of the progestogen is uterine
protection. Some progestogens have been found to have positive effects
on osteoporosis. Progesterone is often referred to as “the feel good hormone”
this is due to its antidepressant and mood enhancing effects.
Resource Medical UK Ltd offers CLIMANOR.
Continuous combined hormone replacement therapy
Continuous combined HRT is taken over a treatment period of 28 days. A
tablet containing both estrogen and progestogen is taken daily.
Continuous combined HRT causes menstrual
bleeding to stop all together after a few months of treatment. Women who
suffer from menopausal symptoms or those who do not wish to continue having
periods will be suited to this form of treatment.
Sequential combined hormone
replacement therapy
Sequential combined hormone replacement is suitable for women suffering
from menopausal symptoms but with irregular cycles.
The progestogen is taken for the second
half of the treatment cycle only. This mimics the activity of a woman’s
natural cycle.
With sequential combined therapy the patient
will still experience a monthly menstrual bleed – although without the
menopausal complaints.
This form of therapy is suited to women
who want to maintain their period.
Resource Medical UK Ltd offers CLINORETTE and CLIMANOR. Transdermal (patch)
Estrogen and estrogen/progestogen combinations are available in weekly
and twice weekly patches. These are a good alternative for women who prefer
not to take oral medication, although can prove awkward and inconvenient
for women leading an active life.
|
||||||||||||||||||||||
|
|
||||||||||||||||||||||
|
2006 © Copyright Resource Medical UK Ltd. All Rights Reserved.
|
||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||